Healthcare >> CEO Interviews >> November 15, 2003
DR. TERRY A. FULLER is President and CEO of RetinaPharma Technologies,
Inc. Mr. Fuller has over twenty-five years of entrepreneurial business
management and technology development experience with emerging and high
growth start-up and early stage medical device and pharmaceutical
companies. He has held positions of CEO, COO, and EVP Technology for
both publicly traded and private corporations Johnson Company
(NYSE:JNJ), Surgical Laser Technologies, Inc. (NASDAQ:SLTI), Laser
SkinToner, Inc. (PVT), SubLase, Inc. (PVT), Fuller Research Corporation
(PVT). He specializes in technology development, identifying, financing
and introducing early or seed-stage technology to the health care market
and implementing numerous acquisitions and strategic alliances.
Professionally, Dr Fuller has strong scientific and clinical expertise
in multiple specialties, including ophthalmology, gynecology and
urology, and has managed numerous regulatory clearances. In addition, he
has broad intellectual property management experience, including
litigation strategies, and patent portfolio management. He has 16 issued
US patents and has authored over 40 articles, several book chapters, and
two books on surgical and medical lasers and ophthalmic and minimally
invasive surgery. Dr. Fuller has been active in PDT research of
treatment of vaginal vault cancer and is a leading authority in less-
invasive energy delivery systems. Academic accomplishments and
affiliations include several university and hospital appointments; most
recently Dr. Fuller served as an Assistant Professor at Jefferson
Medical College. Among the many awards and honors he has received are
the American Medical Association Certificate of Recognition, the
Chalmers J. Lyons Memorial Lecture, Ichabod Washburn Award, Outstanding
Professional Achievement Award and the Sigma Xi Research Award Lecture.
He received a Ph.D. and M.S. in Biomedical Engineering and Biophysics
from Worcester Polytechnic Institute and Clark University in cooperation
with the University of Massachusetts Medical School. Profile
Dr. Fuller: Retinapharma was formed in late 1999. We are a developer of
unique pharmaceuticals that are directed towards the
